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Periodontal disease, peri-implant 
disease and levels of salivary 
biomarkers IL-1β, IL-10, RANK, OPG, 
MMP-2, TGF-β and TNF-α: follow-up 
over 5 years
Objective: The aim of this study was to evaluate the levels of salivary 
biomarkers IL-1β, IL-10, RANK, OPG, MMP-2, TG-β and TNF-α in individuals 
with diagnosis of peri-implant mucositis in the absence or presence of 
periodontal and peri-implant maintenance therapy (TMPP) over 5 years. 
Material and Methods: Eighty individuals diagnosed with peri-implant 
mucositis were divided into two groups: one group that underwent periodontal 
and peri-implant regularly maintenance therapy, called GTP (n=39), and 
a second group that received no regular maintenance GNTP (n=41). Each 
participant underwent a complete periodontal and peri-implant clinical 
examination. Collection of saliva samples and radiographic examination 
to evaluate peri-implant bone levels were conducted at two times: initial 
examination (T1) and after 5 years (T2). The salivary samples were evaluated 
through ELISA for the following markers: IL-1β, IL-10, RANK, OPG, MMP-2, 
TGF and TNF-α. Results: A higher incidence of peri-implantitis was observed 
in the GNTP group (43.9%) than in the GTP group (18%) (p=0.000). All 
individuals (n=12) who presented peri-implant mucositis and had resolution 
at T2 were in the GTP group. After 5 years, there was an increase in the 
incidence of periodontitis in the GNTP group compared to the GTP group 
(p=0.001). The results of the study revealed an increase in the salivary 
concentration of TNF-α in the GNTP group compared to the GTP group. The 
other salivary biomarkers that were evaluated did not show statistically 
significant differences between the two groups. Conclusions: The salivary 
concentration of TNF-α was increased in individuals with worse periodontal 
and peri-implant clinical condition and in those with a higher incidence of 
peri-implantitis, especially in the GNTP group. Longitudinal studies in larger 
populations are needed to confirm these findings and elucidate the role of 
this biomarker in peri-implant disease.
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Introduction
The infectious-inflammatory disease occurring 
around implants is known as peri-implant disease (PID) 
and it may manifest itself as peri-implantitis mucositis 
or periimplantitis. Peri-implant mucositis (MP) is 
characterized by inflammatory infectious disease that 
results in reversible inflammation of peri-implant soft 
tissues and peri-implantitis by the loss of soft and hard 
tissues around the implants.1
Studies have attempted to clarify the role of 
cytokines in this immuno-inflammatory response, 
but the literature presents conflicting and scarce data 
regarding the concentration of potential markers of 
periodontitis (PE) and peri-implantitis2,3 (PI) and their 
role in the progression of these diseases.4,5 In addition, 
cytokines, chemokines, enzymes of cellular destruction 
and the molecules produced as a consequence of tissue 
destruction in PE and PID are released and can be 
identified in saliva.6,7
Recent studies indicate that the use of immunological 
markers may aid in the diagnosis of health and PID. The 
advantage of using saliva instead of blood or gingival 
crevicular fluid analysis is that it is a non-invasive 
collection method, has high availability, is painless 
and does not require special equipment for collection.8
It is a fact that the literature includes numerous 
studies on the association between PID and levels 
of inflammatory markers in peri-implant fluid sulcus 
(FSPI), in gingival tissue biopsies and blood. However, 
surprisingly, despite the advantages of using saliva, 
salivary marker studies related to the presence and 
progression of PID are rare. Additionally, to date, 
clinical changes in peri-implant conditions associated 
with salivary markers in individuals with MP in the 
absence or presence of regularly periodontal and peri-
implant maintenance therapy (TMPP) have not been 
reported in longitudinal follow-up studies.
The literature highlights that TMPP decreases 
biological complications and increases the success of 
long-term implants.9-11. In this sense, the objective of 
this study was to compare the salivary concentrations 
of interleukin (IL) IL-1β, IL-10, RANK, OPG, matrix 
metalloproteinase (MMP) MMP-2, transforming growth 
factor beta (TGF- β) and tumor necrosis factor alpha 
(TNF-α) immunological markers related to the peri-
implantation condition of individuals with MP between 
baseline examination and final exam in the absence 
and presence of TMPP.
Material and methods
Sample
The sample for this study was obtained from a study 
conducted in 2006 with partially edentulous individuals 
rehabilitated with dental implants having the objective 
of identifying possible risk factors and the prevalence 
of PID.12 Eighty nonsmokers who were diagnosed 
with MP in 2006 (T1) were re-called annually to TMPP, 
and new periodontal/peri-implant clinical exams and 
immunological collections were repeated in 2012 (T2), 
resulting in a 5-year interval between T1 and T2. 
These individuals were divided into 2 groups related 
to regularity TMPP: one group that performed TMPP 
regularly, that is, at least one visit/year (GTP=39), 
and one that did not perform TMPP regularly, that is, 
less than one visit/year (GNTP=41). The periodontal 
and peri-implant clinical data of these individuals were 
previously reported.13
In T1 and T2, the following parameters for the 
teeth and implants in periodontal/peri-implant 
examinations were recorded: clinical attachment 
level (CAL), periodontal probing depth (PS) and peri-
implant probing depth (PSi), bleeding on periodontal 
probing (BOP) and bleeding on peri-implant probing 
(BOPi), periodontal (PL) and peri-implant (PLi) plaque 
index.14,15 In the implants, the presence of peri-implant 
suppuration (Si) was also evaluated, and radiographic 
measurements were also conducted to evaluate 
bone levels. The methodology for collecting these 
clinical data was described in detail before.12 Salivary 
sample collection was performed at the time of clinical 
evaluations at T1 and T2 and will be described later.
The procedure and the research were explained 
in detail to each participant, and free and informed 
consent was obtained. Additionally, all 80 individuals 
evaluated for periodontal and peri-implant parameters 
were referred for free periodontal/peri-implant 
maintenance treatment in each scheduled visit. This 
study was approved by the Research Ethics Committee 
under protocol number 05650203000-10.
Inclusion and exclusion criteria 
This study adopted the same inclusion and 
exclusion criteria as the original data published.12 To 
be included in the sample, the participants could not 
have systemic diseases that influence periodontal and 
peri-implant clinical examination, had to attend the 
annual scheduled visit for the TMPP, in GTP group, 
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had not used systemic antimicrobial medicine in the 3 
months prior to clinical examination, and had unitary 
or partial prosthetic rehabilitations suitable for a 
correct clinical examination. Patients with prosthetic 
overdentures (due to the high incidence of soft tissue 
complications and difficulties during the exam) were 
excluded. Smokers (individuals who smoked more 
than 100 cigarettes in their lifetime) and ex-smokers 
(individuals who quit smoking up to 3 years before the 
clinical exams) were excluded from the study.11,16 All 
evaluated implants had at least 6 months and up to 5 
years in function.
Diagnosis of periodontal and peri-implant 
diseases
The PE was diagnosed with presence of 4 or more 
teeth with one or more sites having PS>4 mm and 
CAL≥3 mm at the same site.17 The implant/subject 
was diagnosed with MP in the presence of a site with 
BOPi.18 An implant/subject was diagnosed with PI when 
BOPi and/or Si, PSi≥5 mm and presence of bone loss 
confirmed by radiography19 or a value of PSi≥5 mm, 
even though there was no SSi and/or Si, howeber 
showing bone loss at the radiographic examination.12 If 
the individual had an implant diagnosed with PI, then 
another with MP was considered the worst diagnosis.
Collection of saliva samples for immunological 
analysis
Salivary exam
Non-stimulated total saliva samples were collected 
by a single investigator (F.O.C.) whenever possible, 
at the same time in the two-hour period after the last 
meal. The participants were instructed to rinse their 
mouths with water, and 5 ml of the saliva produced 
was collected in a Falcon-type millimeter tube. Saliva 
samples were frozen at -80°C until analysis by an 
investigator (T.A.S.) who was unaware of the previous 
phases of the experiment. For the assays, the samples 
were thawed and diluted 1:1 in a solution of PBS (0.4 
mM NaCl and 10 mM NaPO4) containing protease 
inhibitors (0.1 mM phenylmethylsulfonyl fluoride, 1 
mM benzethonium chloride, 10 mM EDTA and 0.01 
mg/ml aprotinin A) and 0.05% Tween-20. The samples 
were later centrifuged at 3000 rpm for 15 minutes at 
4°C, and the supernatant was used to analyze the 
concentrations of IL-1β, IL-10, MMP-2/TIMP-2 complex, 
RANK, OPG, TGF-β and TNF-α using commercially 
available kits (R & D Systems, Minneapolis, MN, USA). 
Biomarker concentrations were expressed in pg/ml 
according to the manufacturer’s specifications and 
normalized to total saliva´s proteins at the collection 
times (T1 and T2).
Statistical analysis
The data collected were analyzed with the 
application SPSS (Statistical Package for Social 
Sciences, IBM Inc.Chicago, Ilinois, USA) version 23.0. 
Initially, descriptive analyses were performed to obtain 
the mean, standard deviation, absolute and relative 
frequency of the data. The normality of the data was 
verified by the Kolmogorov-Smirnov test. To verify if 
there were differences in the variables investigated 
between groups, the data were subjected to Mann-
Whitney U and chi-square (or Fisher exact) tests. To 
verify if there was an association in the biomarker 
concentrations between the initial and final diagnosis, 
the data were subjected to the Wilcoxon test. It should 
be noted that for the analysis of data from T1 to T2, 
the GTP and GNTP groups were each subdivided into 
3 subgroups according to peri-implant status in T2: 
health, MP and PI. The level of significance was set at 
5% (p<0.05).
Results
The diagnosis of periodontal and peri-implant 
disease of the sample at T1 and T2 are presented 
in Table 1. There was an increase in the number of 
individuals with PE in the GNTP group when comparing 
T1 (22.0%) and T2 (41.5%) (Table 1). In the GNTP 
group, individuals with MP had lower levels of TNF-α 
when compared to individuals with PI (p=0.033). 
There was no statistically significant difference in 
the concentrations of the other markers evaluated 
between T1 and T2 (Table 2). No significant difference 
was found in the concentrations of the biomarkers 
evaluated for individuals with MP diagnosis in T1 and 
T2. Additionally, no significant difference was found 
in the concentrations of the biomarkers evaluated for 
the individuals with the MP diagnosis at T1 and PI at 
T2 (Table 3). In addition, all individuals (n=12) who 
manifested MP at T1 but were presented as healthy 
at T2 were in the GTP group (Table 4). None of the 
biomarkers evaluated had significantly different 
concentrations between healthy and MP implants.
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Discussion
Saliva samples can be easily obtained in a non-
invasive manner and at low cost, but few published 
studies have examined saliva biomarkers to investigate 
the presence and progression of PID. In this sense, 
this longitudinal study aimed to evaluate peri-implant 
clinical condition and levels of salivary biomarkers 
IL-1β, IL-10, RANK, OPG, MMP-2, TGF and TNF-α 
in individuals diagnosed with MP in the presence 
or absence of TMPP over a 5-year period. After 
investigation of salivary levels, we observed that the 
Variants Baseline exam (T1) Final exam (T2)
GNTP n = 41 GTP n = 39 p GNTP n = 41 GTP n = 39 p
Periodontal diagnosis
Healthy 32 (78.0%) 29 (74.4%) 0.698 24 (58.5%) 28 (71.8%) 0.214
PE 9 (22.0%) 10 (25.6%) 17 (41.5%) 11 (28.2%)
Peri-implant diagnosis
Healthy 0 0 NA 0 (0.0%) 12 (30.7%) 0
MP 41 39 NA 23 (56.0%) 20 (51.2%)
PI 0 0 NA 18 (43.9%) 7 (18%)
GNTP: group without periodontal/peri-implant preventive maintenance; GTP: group with periodontal/peri-implant preventive maintenance. 
PE: periodontitis; MP: peri-implant mucositis; PI: peri-implantitis; NA: not applicable
Table 1- Sample characteristics
MP PI
T1 (MP) T2 (MP) T1 (MP) T2 (PI)
Mean (SD) Mean (SD) p Mean (SD) Mean (SD)   p
IL-1β 17797.7 
(25025.3)
21470.7 (25193.4) 0.217 21468.0 (23332.9) 42689.5 
(116502.6)
0.506
IL-10 4.4 (11.7) 4.5 (11.1) 0.678 8.2 (18.3) 7.4 (17.7) 0.866
TNF-α - 1.2 (7.9) - 12.4 (22.7) 10.9 (21.5) 0.999
TGF-β 9.9 (24.6) 5.8 (10.4) 0.661 5.4 (9.4) 10.6 (24.0) 0.386
MMP-2 14.8 (14.3) 18.4 (27.2) 0.673 25.4 (39.3) 41.1 (104.7) 0.677
RANK 22.2 (18.7) 21.4 (20.2) 0.554 26.4 (15.1) 24.4 (17.6) 0.357
GNTP: group without periodontal/peri-implant maintenance; GTP: group with periodontal/peri-implant maintenance. IL: Interleukin; TNF: 
tumor necrosis factor; TGF: transforming growth factor; MMP: metalloproteinase; RANK: Receptor activator of nuclear factor kappa; OPG: 
Osteoprotegerin; n: individuals; MP: peri-implant mucositis; PI: peri-implantitis; SD standard deviation
Table 3- Comparison of biomarker concentrations (pg/ml) based on clinical evolution from initial examination(T1) to final exam (T2)
Periodontal disease, peri-implant disease and levels of salivary biomarkers IL-1β, IL-10, RANK, OPG, MMP-2, TGF-β and TNF-α: follow-up over 5 years
GNTP GTP TOTAL SAMPLE
MP PI MP PI MP PI
MEAN (SD) MEAN (SD) p MEAN (SD) MEAN (SD)   p MEAN (SD) MEAN (SD) p
IL-1β 22630.3 
(24724.1)
19592.4 
(22324.7)
0.729 20137.2 
(26300.9)
102081.9 
(217171.7)
0.240 21470.7 
(25193.4)
42689.5 
(116502.6)
0.727
IL10 4.7 (12.8) 8.5 (20.2) 0.669 4.3 (9.0) 4.8 (9.5) 0.766 4.5 (11.13) 7.4 (17.7) 0.612
TNF-α 2.2 (10.8) 14.2 (24.4) 0.033 - 2.2 (5.9) - 1.2 (7.9) 10.9 (21.5) 0.005
TGF-β 1.4 (4.3) 5.5 (15.5) 0.920 10.8 (13.0) 23.7 (36.6) 0.978 5.8 (10.4) 10.6 (24.0) 0.612
MMP-2 27.4 (34.7) 54.2 (121.8) 0.446 7.9 (5.0) 7.3 (5.0) 0.725 18.4 (27.2) 41.1 (104.7) 0.312
RANK 38.3 (10.7) 33.9 (9.8) 0.074 2.0 (5.0) - - 21.4 (20.2) 24.4 (17.6) 0.901
OPG 32.2 (44.3) 25.0 (27.4) 0.386 8.2 (9.6) 6.4 (4.2) 0.766 21.0 (34.9) 19.8 (24.7) 0.990
GNTP: group without periodontal/peri-implant maintenance; GTP: group with periodontal/peri-implant maintenance. IL: Interleukin; TNF: 
tumor necrosis factor alpha; TGF: transforming growth factor; MMP: metalloproteinase; RANK: Receptor activator of nuclear factor kappa; 
OPG: Osteoprotegerin MP: peri-implant mucositis; PI: peri-implantitis; SD standard deviation
Table 2- Comparison of biomarker concentrations (pg/ml) in GNTP and GTP groups related to clinical diagnose at final exam
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concentration of TNF-α was significantly higher in 
individuals in the GNTP group who developed PI after 
5 years. Our findings are in agreement with those of 
several authors who found increased salivary cytokine 
levels in cases of PE18,20,21 and PID.22 Another aspect of 
PID and cytokines was the focus of one study.23 The 
authors showed that after measuring the concentration 
of IL-1β in total saliva, saliva of the parotid gland and 
FSPI, only the FSPI measurement showed an increase 
in concentration when comparing a group of implants 
diagnosed with MP with a second group of implants 
diagnosed with PI. The authors attributed the results 
to the dilution of the mediators in the saliva that makes 
them difficult to detect. However, the sample consisted 
of only 20 implants with a cross-sectional analysis of 
cytokine concentrations. The present study included a 
sample of 80 implants and a 5-year follow-up, which 
may influence the contradictory results. One study22 
reinforces the results of the present study because 
the authors evaluated 50 individuals and showed a 
higher concentration of IL-1β in unstimulated saliva in 
individuals with implants diagnosed with PI compared 
to healthy implants.
Notably, the results of our study showed that the 
individuals who had resolved MP with peri-implant 
health belonged to the GTP group, and the prevalence 
of PI in the GNTP group (43.9%) was higher than in 
the GTP group (18%) (p<0.001). Similar findings 
were found in the literature24, one study25 reported 
that in 47 individuals with a history of PE followed for 
7.9 years, the prevalence of PI was of 31.9% among 
the participants who underwent TMPP and 52.2% 
among those who did not undergo TMPP (p=0.102). 
The authors noted that lack of adherence to a regular 
periodontal/peri-implant maintenance program is 
correlated with a high incidence of peri-implant bone 
loss and implant loss. Hence, three main factors 
may have greatly influenced our findings: smoking, 
presence of PE and the absence of TMPP. Smoking is 
considered a major risk factor for PID.19 In this study, 
smokers were excluded from the sample in order to 
minimize this confounding factor in data analysis. 
In the GTP group, 12 individuals with MP in T1 were 
diagnosed as healthy at T2. This result is in agreement 
with studies on the influence of preventive maintenance 
in the control of PE and MP. The findings of recent 
systematic reviews and meta-analysis14 showed that 
TMPP is important in preventing and reducing the 
occurrence of PE and MP. Another systematic review 
study with meta-analysis stressed the importance of 
peri-implant maintenance, as it is the best way to 
prevent PI is MP control.26 The literature shows that 
professional follow-up in maintenance consultations 
prevents the development of PE, which is a risk factor 
for PI.27 Another study has shown that TMPP reduces 
the occurrence of PI in individuals with a history of 
PE, and the lack of TMPP is correlated with a higher 
incidence of peri-implant bone loss in individuals 
with and without a history of PE.28 According to the 
literature,29 the primary objective for avoiding the 
occurrence of complications with implants is based on 
a reinforcement of plaque control and reduction of risk 
factors, such as smoking and adjustment of prostheses, 
which hinder good local hygiene.
In addition to periodic maintenance, the 
concentrations of periodontal and peri-implant 
biomarkers have been studied in an attempt to 
predict their progression. In one study20, the authors 
demonstrated that saliva analysis can be used to verify 
the progression of PE, since the authors verified that 
MP(T1) Healthy(T2) PI (T2)
Mean (SD) Mean (SD) p*
IL-1 20137.28 (26300.93) 13655.44 (24495.43) 102081.93 (217171.72) 0.179
IL-10 4.38 (9.04) 1.87 (6.47) 4.88 (9.56) 0.523
TNF-α - - 2.23 (5.91) -
TGF-β 10.90 (13.04) 8.82 (8.45) 23.78 (36.70) 0.998
MMP-2 7.98 (5.03) 6.16 (2.24) 7.34 (5.09) 0.704
RANK 2.05 (5.05) 1.25 (4.35) - 0.532
OPG 8.24 (9.68) 10.82 (12.37) 6.48 (4.21) 0.860
GNTP: group without periodontal/peri-implant maintenance; GTP: group with periodontal/peri-implant maintenance. IL: Interleukin; TNF: 
tumor necrosis factor; TGF: transforming growth factor; MMP: metalloproteinase; RANK: Receptor activator of nuclear factor kappa; 
OPG: Osteoprotegerin; T1: initial examination; T2: final exam; n: individuals; MP: peri-implant mucositis; PI: peri-implantitis; SD standard 
deviation
Table 4- Comparison of biomarker concentrations (pg/ml) in the individuals in the GTP groups with healthy implants diagnosed at final 
exam(T2)
GOMES AM, OLIVEIRA DWD, FERREIRA SD, SILVA TA, COTA LOM, COSTA FO
J Appl Oral Sci. 2019;27:e201803166/7
TNF-α concentration was low at the beginning of PE 
and increased as it progressed. In the present study, 
a similarity to the previously mentioned study was 
observed: the cytokine in question was low in the MP 
group and increased in the PI implant group. Thus, the 
TNF-α biomarker was highlighted as a potential tool for 
the prognosis and progression of PE and PI.
An important aspect of our study related to saliva 
concentration was discussed in a previous study30. 
The authors observed that total salivary cytokines 
may represent only a fraction of the total content in 
saliva and that cytokines can be negatively affected 
(diluted) by salivary components (mucin), which 
decreases the detection power of the ELISA assay. 
Another study showed that mucin had already been 
found to be increased in saliva in cases of chronic 
PE compared to periodontally healthy cases.31 The 
literature showed that, when using ELISA for salivary 
analysis, a correction must be made by the protein such 
that the test can be considered reliable.32 This concern 
over the influence of salivary protein was considered 
in our study, since the concentrations of the cytokines 
were normalized by the salivary protein to attempt to 
decrease the salivary viscosity effect at the collection 
time points (T1 and T2).
In addition to the absence of significant differences 
in the salivary concentration of IL-1β, IL-10 TGF-β and 
RANK/OPG between T1 and T2, it is worth noting that 
the hypothesis of this study was finding increased 
levels of IL-1β, IL- 10, TGF-β and RANK/OPG in the 
GNTP group compared to the GTP group, especially in 
individuals who developed PI. However, one study has 
also observed that the salivary levels of this biomarker 
are not able to differentiate MP from PI.33 This result 
may have been obtained because of the difficulty in 
detecting cytokines in PID and PE. Due to the periods 
of activity and inactivity of these pathologies, at low 
concentrations, the biomarkers may have an increase 
or decrease in their release in saliva, FSPI and gingival 
crevicular fluid.34
MMPs have been studied for their ability to cleave 
components of the extracellular matrix. In particular, 
MMP-2 has an important relationship with PID because 
it is able to cleave collagen type 1, which is an 
abundant component in gingival conjunctive tissue, 
is linked to the monitoring of collagen degradation 
and has been associated with tissue destruction in 
chronic PE.35 It was demonstrated that there were 
no differences in biomarkers salivary concentration 
between PE and periodontal health.36,37 This finding 
reinforces the findings of our study since it diminishes 
the influence of PE in the results, as the sample in 
this study had individuals who did not manifest PE 
at T1 but manifested PE at T2. Due to the important 
relationship with collagen degradation and scarcity of 
studies on salivary MMP, we emphasize that it should 
be used in future studies to better understand the 
relationship with PID.
Thus, the quantification of salivary markers 
was considered a promising diagnostic tool for the 
understanding, prevention and progression of PE and 
PID.38 For future research, it is important to note that, 
together with cytokine analysis of salivary glands, this 
approach can greatly benefit the diagnosis because 
observing a high concentration of a proinflammatory 
cytokine may produce increased risk of developing 
PE and PID before its clinical signs of activity are 
exacerbated.39
Conclusion
This study showed a beneficial role of TMPP in 
maintaining the balance of periodontal and peri-implant 
clinical condition and that, in the absence of TMPP, the 
salivary concentration of TNF-α increased. Additionally, 
the increased salivary level of TNF-α was associated 
with worse peri-implant clinical condition. Thus, TNF-α 
may be considered a biomarker of PID, but new studies 
in different populations and with different designs are 
needed to clarify this cytokine’s role in peri-implant 
diagnosis and progression.
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